Allergan Plc says it's “reloaded and ready to move” on further acquisitions after agreeing to sell its generic-drug business for $40.5 billion. The deal with Teva Pharmaceutical Industries Ltd. “gives us a tremendous amount of flexibility to think about transformational M&A as well as continue our pattern of tuck-in acquisitions,” Allergan Chief Executive Officer Brent Saunders said on a conference call today.